Phase II Randomized, Open-label, Multicenter Clinical Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of SHR-2173 Injection in Patients With Primary Membranous Nephropathy

Recruiting now · Phase 2

Conditions studied: Primary Membranous Nephropathy

In brief

To investigate the safety, efficacy, pharmacokinetics, and pharmacodynamics of SHR-2173 injection in patients with primary membranous nephropathy

Key facts

Study ID

NCT07289763

Run by

Guangdong Hengrui Pharmaceutical Co., Ltd

People needed

75

Starts

2025-12-31

Expected to finish

2027-09-01

Last updated by the study team

2026-01-26

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18-75 years, regardless of gender;
• Weight ≥40.0 kg at screening;
• Diagnosed as primary membranous nephropathy through kidney biopsy.

You may not qualify if…

• Secondary membranous nephropathy.
• Subjects developed rapidly progressive glomerulonephritis or required kidney transplantation.
• Subjects who have undergone kidney dialysis in the previous 12 months or are expected to require dialysis during the study period.
• Subjects who have a malignant tumor or a history of malignant tumor
• Subjects who have undergone major surgery within the previous 3 months, or plan to undergo major surgery during the study period.

Where it is running

• General hospital of eastern theater command — Nanjing, Jiangsu, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.